All In Biotech

Drug Trial Radar · NCT05582395

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 580 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

580

Actual

Start

Dec 14, 2022

Primary completion

Mar 6, 2025

Study completion Oct 20, 2025

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Oct 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).

Conditions

  • Cardiomyopathy, Hypertrophic

Interventions

  • MavacamtenDrug

    Specified dose on specified days

  • PlaceboOther

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in KCCQ-23 CSS at Week 48Time frame: From First dose to week 48
  2. Change From Baseline in pVO2 at Week 48Time frame: From First dose to week 48

Locations

224 sites in 23 countries. Site status is shown where the registry gives one.

  • Local Institution - 0082

    Birmingham, Alabama

  • Local Institution - 0458

    Phoenix, Arizona

  • Local Institution - 0409

    La Jolla, California

  • Local Institution - 0010

    Los Angeles, California

  • Local Institution - 0406

    San Francisco, California

  • Local Institution - 0079

    Stanford, California

  • Local Institution - 0468

    Gainesville, Florida

  • Local Institution - 0281

    Tampa, Florida

  • Local Institution - 0092

    Atlanta, Georgia

  • Local Institution - 0424

    Indianapolis, Indiana

  • Local Institution - 0070

    Iowa City, Iowa

  • Local Institution - 0410

    Kansas City, Kansas

  • Local Institution - 0484

    Louisville, Kentucky

  • Local Institution - 0127

    Baltimore, Maryland

  • Local Institution - 0479

    Boston, Massachusetts

  • Local Institution - 0500

    Boston, Massachusetts

  • Local Institution - 0464

    Ann Arbor, Michigan

  • Local Institution - 0064

    Detroit, Michigan

  • Local Institution - 0455

    Grand Rapids, Michigan

  • Local Institution - 0431

    Rochester, Minnesota

  • Local Institution - 0461

    St Louis, Missouri

  • Local Institution - 0435

    Omaha, Nebraska

  • Local Institution - 0490

    Morristown, New Jersey

  • Local Institution - 0449

    Manhasset, New York

  • Local Institution - 0486

    New York, New York

  • Local Institution - 0007

    Stony Brook, New York

  • Local Institution - 0426

    Valhalla, New York

  • Local Institution - 0094

    Charlotte, North Carolina

  • Local Institution - 0065

    Durham, North Carolina

  • Local Institution - 0083

    Cleveland, Ohio

  • Local Institution - 0047

    Hershey, Pennsylvania

  • Local Institution - 0444

    Lancaster, Pennsylvania

  • Local Institution - 0263

    Philadelphia, Pennsylvania

  • Local Institution - 0081

    Pittsburgh, Pennsylvania

  • Local Institution - 0207

    Germantown, Tennessee

  • Local Institution - 0089

    Dallas, Texas

  • Local Institution - 0365

    Dallas, Texas

  • Local Institution - 0492

    Plano, Texas

  • Local Institution - 0402

    Salt Lake City, Utah

  • Local Institution - 0478

    Charlottesville, Virginia

Showing 40 of 224 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.